StockMacro
Menu

Repligen

$163.81 +42% in 6 monthsMarket cap $10.5B

RGEN on XNAS, Health Care, Repligen Corp, job postings

Measures activity, not value. Not investment advice.

Revenue rose 14% to $805.6M but the company still lost $11.8M over 12 months.

  • WatchShares rose 42% in six months, then fell 9.0% in one month
  • Watch1 completed acquisition or disposal in the last 90 days

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
2,000
Website
repligen.com
Listed
Nasdaq, US
Last results
27 Oct 2026
Next results
expected around 23 Feb 2027 (an estimate: a year ago it reported on 24 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $209.3M, net loss $38.4M.
Quarter to 31 Dec 2021: revenue $186.5M, net income $29.1MQuarter to 31 Dec 2021: revenue $186.5M, net income $29.1MQuarter to 31 Mar 2022: revenue $206.4M, net income $47.0MQuarter to 31 Mar 2022: revenue $206.4M, net income $47.0MQuarter to 30 Jun 2022: revenue $207.6M, net income $49.9MQuarter to 30 Jun 2022: revenue $207.6M, net income $49.9MQuarter to 30 Sep 2022: revenue $200.7M, net income $40.4MQuarter to 30 Sep 2022: revenue $200.7M, net income $40.4MQuarter to 31 Dec 2022: revenue $186.8M, net income $48.7MQuarter to 31 Dec 2022: revenue $186.8M, net income $48.7MQuarter to 31 Mar 2023: revenue $182.7M, net income $28.8MQuarter to 31 Mar 2023: revenue $182.7M, net income $28.8MQuarter to 30 Jun 2023: revenue $159.2M, net income $20.1MQuarter to 30 Jun 2023: revenue $159.2M, net income $20.1MQuarter to 30 Sep 2023: revenue $141.2M, net income $18.2MQuarter to 30 Sep 2023: revenue $141.2M, net income $18.2MQuarter to 31 Dec 2023: revenue $155.7M, net income -$25.5MQuarter to 31 Dec 2023: revenue $155.7M, net income -$25.5MQuarter to 31 Mar 2024: revenue $151.3M, net income $2.1MQuarter to 31 Mar 2024: revenue $151.3M, net income $2.1MQuarter to 30 Jun 2024: revenue $154.1M, net income $3.3MQuarter to 30 Jun 2024: revenue $154.1M, net income $3.3MQuarter to 30 Sep 2024: revenue $154.9M, net income -$654KQuarter to 30 Sep 2024: revenue $154.9M, net income -$654KQuarter to 31 Mar 2025: revenue $169.2M, net income $5.8MQuarter to 31 Mar 2025: revenue $169.2M, net income $5.8MQuarter to 30 Jun 2025: revenue $182.4M, net income $14.9MQuarter to 30 Jun 2025: revenue $182.4M, net income $14.9MQuarter to 30 Sep 2025: revenue $188.8M, net income $14.9MQuarter to 30 Sep 2025: revenue $188.8M, net income $14.9MQuarter to 31 Mar 2026: revenue $194.3M, net income $8.3MQuarter to 31 Mar 2026: revenue $194.3M, net income $8.3MQuarter to 30 Jun 2026: revenue $204.1M, net income $5.0MQuarter to 30 Jun 2026: revenue $204.1M, net income $5.0MQuarter to 30 Sep 2026: revenue $209.3M, net income -$38.4MQuarter to 30 Sep 2026: revenue $209.3M, net income -$38.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $209.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$209.3M-$38.4M
30 Jun 2026$204.1M$5.0M
31 Mar 2026$194.3M$8.3M
30 Sep 2025$188.8M$14.9M
30 Jun 2025$182.4M$14.9M
31 Mar 2025$169.2M$5.8M
30 Sep 2024$154.9M-$654K
30 Jun 2024$154.1M$3.3M
31 Mar 2024$151.3M$2.1M
31 Dec 2023$155.7M-$25.5M
30 Sep 2023$141.2M$18.2M
30 Jun 2023$159.2M$20.1M
31 Mar 2023$182.7M$28.8M
31 Dec 2022$186.8M$48.7M
30 Sep 2022$200.7M$40.4M
30 Jun 2022$207.6M$49.9M
31 Mar 2022$206.4M$47.0M
31 Dec 2021$186.5M$29.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $805.6M $707.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +14% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$11.8M $1.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.20 $0.01
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 53.8% 45.7% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 2.3% 0.1% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -1.5% 0.2% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -0.6% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $106.7M $110.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $863.0M $748.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $555.6M $537.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$307.4M (net cash) -$210.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.27 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $32.72
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 13.0 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 12.6 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
RepligenRGEN (this company) $10.5Bloss13.0+14%-1.5%
Halozyme TherapeuticsHALO $10.4B21.55.8+45%26.9%
Kymera TherapeuticsKYMR $9.8Bloss96.3+134%-342%
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%
Krystal BiotechKRYS $9.2B40.719.5+26%47.9%
VaxcytePCVX $8.8Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$5.0M

bought $0, sold $5.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+10%

518 13F filers vs 470

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

70.7M shares held by 13F filers (30 Sep 2026) of 63.9M outstanding (23 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

11%

7.1M shares sold short (30 Oct 2026) of 63.9M outstanding (23 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.9

7.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-1.3%

7.1M shares sold short in the report before, 7.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

46%

46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+11%

$209.3M vs $188.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+5.2%

$4.9M vs $4.7M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$175K

the 12 months before: $34K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 2.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.4×

6 articles in the last 7 days; its usual week has 2.5.

Price $163.81 on 20 Nov 2026, +6.1% over 12 months (12-month range $102.87 to $194.57)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $6.7M in the last 12 months (the 12 months before: -$19.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, +25% on the 12 months before.
Revenue per quarter. Revenue $209.3M in the latest quarter, +11% on a year earlier.
Capital spending per quarter. Capital spending $4.9M in the latest quarter, +5.2% on a year earlier.
Institutional holders (13F filers). 518 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.
Federal obligations. Federal obligations: $344K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
6 Oct 20268-K and other filingsCompleted an acquisition or asset sale
15 Sep 20268-K and other filingsDirector or officer change
15 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jun 2026Sharp changeShort interest spike: short interest spike, 6.0M vs usual 3.9M (2026-05-29); 1.7x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 5.5M vs usual 3.7M (2026-04-15); 1.7x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 5.6M vs usual 3.6M (2026-03-31); 1.6x the same period a year earlier
6 Jan 20268-K and other filingsDirector or officer change
6 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Sep 20258-K and other filingsDirector or officer change
2 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Mar 20258-K and other filingsReport will be filed late
12 Nov 20248-K and other filingsReport will be filed late
18 Sep 20248-K and other filingsEarlier financial statements can no longer be relied on
15 Jun 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 600K)
14 Jun 20248-K and other filingsDirector or officer change
19 Mar 20248-K and other filingsDirector or officer change
19 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Oct 20238-K and other filingsDirector or officer change
12 Sep 20238-K and other filingsDirector or officer change
12 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Feb 20238-K and other filingsDirector or officer change
9 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Aug 2022Sharp changeShort interest spike: short interest spike, 3.1M vs usual 1.7M (2022-07-15); 2.0x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.7M (2022-06-30); 1.7x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.7M (2022-06-15); 1.5x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.7M (2022-05-31); 1.5x the same period a year earlier
1 Jun 20228-K and other filingsDirector or officer change
1 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 May 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.7M (2022-05-13); 1.5x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 2.8M vs usual 1.7M (2022-04-29); 1.8x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 2.3M vs usual 1.7M (2022-04-14); 1.4x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 2.5M vs usual 1.6M (2022-03-15); 1.8x the same period a year earlier
15 Mar 2022Sharp changeShort interest spike: short interest spike, 2.3M vs usual 1.6M (2022-02-28); 1.7x the same period a year earlier
22 Feb 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 32.1M vs usual 7.3M (2021-12-31); 2.8x the same period a year earlier
4 Jan 20228-K and other filingsDirector or officer change
4 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$396K published
Month from 1 May 2022: -$2.2M published
Month from 1 Jul 2022: -$5.0M published
Month from 1 Aug 2022: -$4.7M published
Month from 1 Sep 2022: -$6.1M published
Month from 1 Nov 2022: -$5.0M published
Month from 1 Dec 2022: $109K published
Month from 1 Feb 2023: -$1.1M published
Month from 1 May 2023: $238K published
Month from 1 Aug 2023: -$146K published
Month from 1 Nov 2023: -$557K published
Month from 1 Feb 2024: -$1.1M published
Month from 1 Mar 2024: -$4.0M published
Month from 1 May 2024: -$3.4M published
Month from 1 Jun 2024: $600K published
Month from 1 Aug 2024: -$1.9M published
Month from 1 Sep 2024: -$3.2M published
Month from 1 Nov 2024: -$3.4M published
Month from 1 Mar 2025: -$4.0M published
Month from 1 May 2025: -$3.3M published
Month from 1 Aug 2025: $202K published
Month from 1 Sep 2025: -$3.5M published
Month from 1 Nov 2025: -$8.5M published
Month from 1 Dec 2025: -$44K published
Month from 1 Apr 2026: -$536K published
Month from 1 Jun 2026: -$106K published
Month from 1 Jul 2026: -$80K published
Month from 1 Aug 2026: -$977K published
Month from 1 Sep 2026: -$3.9M published
Month from 1 Oct 2026: -$1.0M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 4 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2025: 3 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 1 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $186.5M, +72% on a year earlier; public on 18 Feb 2022
Quarter ended 31 Mar 2022: $206.4M, +45% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $207.6M, +27% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $200.7M, +13% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $186.8M, +0.1% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $182.7M, -12% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $159.2M, -23% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $141.2M, -30% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $155.7M, -17% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $151.3M, -17% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $154.1M, -3.2% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $154.9M, +9.7% on a year earlier; public on 19 Nov 2024
Quarter ended 31 Mar 2025: $169.2M, +12% on a year earlier; public on 30 Apr 2025
Quarter ended 30 Jun 2025: $182.4M, +18% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $188.8M, +22% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $194.3M, +15% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $204.1M, +12% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $209.3M, +11% on a year earlier; public on 31 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $32.1M, +182% on a year earlier; public on 18 Feb 2022
Quarter ended 31 Mar 2022: $27.2M, +259% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $25.4M, +54% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $11.8M, +8.5% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $20.4M, -36% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $8.5M, -69% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $8.2M, -68% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $8.4M, -29% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $11.1M, -46% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $8.3M, -1.9% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $4.8M, -42% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $7.0M, -17% on a year earlier; public on 19 Nov 2024
Quarter ended 31 Dec 2024: $5.5M, -50% on a year earlier; public on 15 Mar 2025
Quarter ended 31 Mar 2025: $3.6M, -57% on a year earlier; public on 30 Apr 2025
Quarter ended 30 Jun 2025: $7.1M, +48% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $4.7M, -33% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $8.2M, +47% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $4.7M, +32% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $5.3M, -25% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $4.9M, +5.2% on a year earlier; public on 31 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 452; public on 14 Feb 2022
31 Mar 2022 report: 427; public on 16 May 2022
30 Jun 2022 report: 378; public on 15 Aug 2022
30 Sep 2022 report: 392; public on 14 Nov 2022
31 Dec 2022 report: 399; public on 14 Feb 2023
31 Mar 2023 report: 417; public on 15 May 2023
30 Jun 2023 report: 407; public on 14 Aug 2023
30 Sep 2023 report: 407; public on 14 Nov 2023
31 Dec 2023 report: 432; public on 14 Feb 2024
31 Mar 2024 report: 463; public on 15 May 2024
30 Jun 2024 report: 436; public on 14 Aug 2024
30 Sep 2024 report: 417; public on 14 Nov 2024
31 Dec 2024 report: 415; public on 14 Feb 2025
31 Mar 2025 report: 427; public on 15 May 2025
30 Jun 2025 report: 424; public on 14 Aug 2025
30 Sep 2025 report: 429; public on 14 Nov 2025
31 Dec 2025 report: 455; public on 17 Feb 2026
31 Mar 2026 report: 426; public on 15 May 2026
30 Jun 2026 report: 470; public on 14 Aug 2026
30 Sep 2026 report: 518; public on 16 Nov 2026
Federal obligations
Month from 1 Mar 2022: $30K published
Month from 1 May 2022: $0 published
Month from 1 May 2024: $49K published
Month from 1 Sep 2024: $34K published
Month from 1 Feb 2025: $0 published
Month from 1 Apr 2026: $0 published
Month from 1 Jun 2026: $175K published
Month from 1 Sep 2026: $169K published
Month from 1 Nov 2026: -$0.1 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $209.3M (30 Sep 2026), 1.2× its normal quarter; higher than 100% of its own history.
  • Short interest spike: had 6.0M shares sold short in the 29 May 2026 report, 1.7× the same report last year Public on 10 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $6.7M in the last 12 months (the 12 months before: -$19.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 5 published in the last 12 months, +25% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 4 sales, $5.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
6 Oct 2026Olivier LoeillotChief Executive OfficerSellplanned in advance (10b5-1); after exercising options5,535$187.29$1.0MForm 4
25 Sep 2026Olivier LoeillotChief Executive OfficerSellplanned in advance (10b5-1); after exercising options12,946$190.00$2.5MForm 4
22 Sep 2026Olivier LoeillotChief Executive OfficerSellplanned in advance (10b5-1); after exercising options5,426$180.00$977KForm 4
8 Sep 2026Olivier LoeillotChief Executive OfficerSellplanned in advance (10b5-1)3,035$165.90$504KForm 4
21 Aug 2026Olivier LoeillotChief Executive OfficerSellplanned in advance (10b5-1); after exercising options5,426$180.00$977KForm 4
17 Jul 2026Jason K GarlandCFOSellplanned in advance (10b5-1)530$150.00$80KForm 4
26 Jun 2026Jason K GarlandCFOSellplanned in advance (10b5-1)733$145.00$106KForm 4
22 Apr 2026Olivier LoeillotChief Executive OfficerSellplanned in advance (10b5-1)3,832$140.00$536KForm 4

518 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 98 opened a position, 52 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)7.4M11.5%$1.4B+4.0M+121%
BlackRock, Inc.5.7M8.96%$1.1B+342K+6.3%
United Capital Financial Advisors, LLC2.8M4.36%$536.3M-6120%
Vanguard Capital Management LLC2.4M3.82%$469.6M+32K+1.3%
Vanguard Portfolio Management LLC2.3M3.55%$436.7M-41K-1.8%
Invesco Ltd.2.1M3.34%$410.2M+747K+54%
T. Rowe Price Associates Inc2.0M3.18%+278K+16%
Massachusetts Financial Services Co2.0M3.17%$392.3M+412K+25%
State Street Corp1.8M2.89%$355.5M+49K+2.7%
Ameriprise Financial Inc1.7M2.64%$324.7M+113K+7.2%

Company events

All 44 company events

In 12 months: 2 director or officer changes, 2 major agreements, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
6 Nov 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
6 Oct 2026Completed an acquisition or asset sale8-K
15 Sep 2026Director or officer change8-K
22 Jul 2026Signed a major agreement8-K
6 Jan 2026Director or officer change8-K
2 Sep 2025Director or officer change8-K
3 Mar 2025Annual report will be filed lateNT 10-K
12 Nov 2024Quarterly report will be filed lateNT 10-Q

The 5 newest of 128 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Mar 2022confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Repligen (RGEN): spent $32.1M on capital projects in the quarter ended 31 Dec 2021, 2.8× the same quarter last year, while it had 2.5M shares sold short in the 15 Mar 2022 report, 1.8× the same report last year. Two unrelated kinds of activity within 35 days.

  • Financials: Quarterly capital spending jump, became public on 22 Feb 2022
  • Short interest and volume: Short interest spike, became public on 10 Mar 2022
  • Short interest and volume: Short interest spike, became public on 25 Mar 2022
2019-12-31: $7.1M2020-03-31: $4.1M2020-06-30: $3.2M2020-09-30: $3.8M2020-12-31: $11.4M2021-03-31: $7.6M2021-06-30: $16.5M2021-09-30: $10.9M2021-12-31: $32.1M
The quarter ended 31 Dec 2021 against the 8 quarters before it. this quarterearliernormal: $7.3M
See the evidence (3 changes)

Financials: Quarterly capital spending jump became public on 22 Feb 2022

Repligen spent $32.1M on capital projects in the quarter ended 31 Dec 2021, 2.8× the same quarter last year.

This period
$32.1M (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$7.3M
Typical spread (median absolute deviation)
$3.6M
How far from its usual level
+4.7
Same quarter last year
$11.4M
History used
4,202 days
2019-12-31: $7.1M2020-03-31: $4.1M2020-06-30: $3.2M2020-09-30: $3.8M2020-12-31: $11.4M2021-03-31: $7.6M2021-06-30: $16.5M2021-09-30: $10.9M2021-12-31: $32.1M
the quarter ended 31 Dec 20218 earlier quartersnormal: $7.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 Mar 2022

Repligen had 2.3M shares sold short in the 28 Feb 2022 report, 1.7× the same report last year.

This period
2.3M (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
64K
How far from its usual level
+4.4
Same report last year
1.4M
History used
1,522 days
2021-02-12: 1.4M2021-02-26: 1.4M2021-03-15: 1.4M2021-03-31: 1.5M2021-04-15: 1.6M2021-04-30: 1.6M2021-05-14: 1.7M2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M
the 28 Feb 2022 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2022

Repligen had 2.5M shares sold short in the 15 Mar 2022 report, 1.8× the same report last year.

This period
2.5M (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.9
Same report last year
1.4M
History used
1,537 days
2021-02-26: 1.4M2021-03-15: 1.4M2021-03-31: 1.5M2021-04-15: 1.6M2021-04-30: 1.6M2021-05-14: 1.7M2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M
the 15 Mar 2022 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

20 Aug 2019confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Repligen (RGEN): reported revenue of $70.7M for the quarter ended 30 Jun 2019, 1.5× the same quarter last year, while it saw 45 13F filers open a new position in the quarter ended 30 Jun 2019, 2.5× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 6 Aug 2019
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2019
2017-06-30: $32.5M2017-09-30: $36.6M2017-12-31: $41.6M2018-03-31: $44.8M2018-06-30: $47.7M2018-09-30: $49.5M2018-12-31: $51.9M2019-03-31: $60.6M2019-06-30: $70.7M
The quarter ended 30 Jun 2019 against the 8 quarters before it. this quarterearliernormal: $46.3M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 6 Aug 2019

Repligen reported revenue of $70.7M for the quarter ended 30 Jun 2019, 1.5× the same quarter last year.

This period
$70.7M (the quarter ended 30 Jun 2019)
Normal quarter (median of 8 earlier)
$46.3M
Typical spread (median absolute deviation)
$5.2M
How far from its usual level
+3.2
Same quarter last year
$47.7M
History used
3,287 days
2017-06-30: $32.5M2017-09-30: $36.6M2017-12-31: $41.6M2018-03-31: $44.8M2018-06-30: $47.7M2018-09-30: $49.5M2018-12-31: $51.9M2019-03-31: $60.6M2019-06-30: $70.7M
the quarter ended 30 Jun 20198 earlier quartersnormal: $46.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2019

Repligen saw 45 13F filers open a new position in the quarter ended 30 Jun 2019, 2.5× the same quarter last year.

This period
45 (the quarter ended 30 Jun 2019)
Normal quarter (median of 8 earlier)
21
Typical spread (median absolute deviation)
4
How far from its usual level
+4.0
Same quarter last year
18
History used
2,099 days
2017-06-30: 262017-09-30: 202017-12-31: 172018-03-31: 172018-06-30: 182018-09-30: 222018-12-31: 492019-03-31: 452019-06-30: 45
the quarter ended 30 Jun 20198 earlier quartersnormal: 21

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 6 Oct 2026Filings record

    Completed an acquisition or asset sale

  2. 15 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 15 Sep 2026Filings record

    Director or officer change

  4. 10 Jun 2026Short interest and volume change

    had 6.0M shares sold short in the 29 May 2026 report, 1.7× the same report last year.

    Same report last year: 3.4M; its normal report is 3.9M.

    See the evidence
    This period
    6.0M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    384K
    How far from its usual level
    +3.6
    Same report last year
    3.4M
    History used
    3,073 days
    2025-05-30: 3.4M2025-06-13: 3.4M2025-06-30: 3.8M2025-07-15: 3.4M2025-07-31: 3.6M2025-08-15: 3.9M2025-08-29: 3.6M2025-09-15: 3.5M2025-09-30: 3.4M2025-10-15: 3.4M2025-10-31: 3.3M2025-11-14: 4.1M2025-11-28: 4.3M2025-12-15: 4.1M2025-12-31: 3.9M2026-01-15: 3.9M2026-01-30: 4.1M2026-02-13: 4.0M2026-02-27: 4.0M2026-03-13: 4.3M2026-03-31: 5.6M2026-04-15: 5.5M2026-04-30: 5.5M2026-05-15: 5.7M2026-05-29: 6.0M
    the 29 May 2026 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 25 Apr 2026Short interest and volume change

    had 5.5M shares sold short in the 15 Apr 2026 report, 1.7× the same report last year.

    Same report last year: 3.2M; its normal report is 3.7M.

    See the evidence
    This period
    5.5M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    303K
    How far from its usual level
    +4.0
    Same report last year
    3.2M
    History used
    3,029 days
    2025-04-15: 3.2M2025-04-30: 3.4M2025-05-15: 3.4M2025-05-30: 3.4M2025-06-13: 3.4M2025-06-30: 3.8M2025-07-15: 3.4M2025-07-31: 3.6M2025-08-15: 3.9M2025-08-29: 3.6M2025-09-15: 3.5M2025-09-30: 3.4M2025-10-15: 3.4M2025-10-31: 3.3M2025-11-14: 4.1M2025-11-28: 4.3M2025-12-15: 4.1M2025-12-31: 3.9M2026-01-15: 3.9M2026-01-30: 4.1M2026-02-13: 4.0M2026-02-27: 4.0M2026-03-13: 4.3M2026-03-31: 5.6M2026-04-15: 5.5M
    the 15 Apr 2026 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 11 Apr 2026Short interest and volume change

    had 5.6M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

    Same report last year: 3.5M; its normal report is 3.6M.

    See the evidence
    This period
    5.6M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +5.0
    Same report last year
    3.5M
    History used
    3,014 days
    2025-03-31: 3.5M2025-04-15: 3.2M2025-04-30: 3.4M2025-05-15: 3.4M2025-05-30: 3.4M2025-06-13: 3.4M2025-06-30: 3.8M2025-07-15: 3.4M2025-07-31: 3.6M2025-08-15: 3.9M2025-08-29: 3.6M2025-09-15: 3.5M2025-09-30: 3.4M2025-10-15: 3.4M2025-10-31: 3.3M2025-11-14: 4.1M2025-11-28: 4.3M2025-12-15: 4.1M2025-12-31: 3.9M2026-01-15: 3.9M2026-01-30: 4.1M2026-02-13: 4.0M2026-02-27: 4.0M2026-03-13: 4.3M2026-03-31: 5.6M
    the 31 Mar 2026 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 6 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 6 Jan 2026Filings record

    Director or officer change

  9. 14 Nov 2025Institutional holdings record

    UNITED CAPITAL FINANCIAL ADVISORS, LLC opened a $368.0M position (2025Q3 13F)

  10. 2 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 2 Sep 2025Filings record

    Director or officer change

  12. 13 Aug 2025Insiders record

    Madaus Martin D (director) bought 1,800 shares of RGEN ($201,834) (dated 12 Aug 2025)

  13. 19 Mar 2025Insiders record

    Pax Margaret (director) bought 250 shares of RGEN ($37,672) (dated 18 Mar 2025)

  14. 3 Mar 2025Filings record

    Report will be filed late

  15. 12 Nov 2024Filings record

    Report will be filed late

  16. 18 Sep 2024Filings record

    Earlier financial statements can no longer be relied on

  17. 15 Jun 2024Insiders change

    had 3 insiders buy $600K of its shares on the open market within 30 days (3 filings).

    Who bought: Hunt Anthony, Madaus Martin D, Barthelemy Nicolas.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $600K
    Window
    16 May 2024 to 15 Jun 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  18. 15 Jun 2024Insiders record

    BARTHELEMY NICOLAS (director) bought 1,200 shares of RGEN ($150,540) (dated 14 Jun 2024)

  19. 15 Jun 2024Insiders record

    Madaus Martin D (director) bought 1,615 shares of RGEN ($201,776) (dated 14 Jun 2024)

  20. 15 Jun 2024Insiders record

    Hunt Anthony (Chief Executive Officer) bought 2,000 shares of RGEN ($248,160) (dated 14 Jun 2024)

  21. 14 Jun 2024Filings record

    Director or officer change

  22. 19 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 19 Mar 2024Filings record

    Director or officer change

  24. 2 Oct 2023Filings record

    Director or officer change

  25. 12 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 12 Sep 2023Filings record

    Director or officer change

  27. 9 May 2023Insiders record

    Madaus Martin D (director) bought 1,500 shares of RGEN ($238,260) (dated 8 May 2023)

  28. 9 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 9 Feb 2023Filings record

    Director or officer change

  30. 16 Dec 2022Insiders record

    EGLINTON MANNER CARRIE (director) bought 625 shares of RGEN ($109,388) (dated 15 Dec 2022)

  31. 9 Nov 2022Institutional holdings record

    SANDS CAPITAL MANAGEMENT, LLC opened a $307.0M position (2022Q3 13F)

  32. 27 Jul 2022Short interest and volume change

    had 3.1M shares sold short in the 15 Jul 2022 report, 2.0× the same report last year.

    Same report last year: 1.6M; its normal report is 1.7M.

    See the evidence
    This period
    3.1M (the 15 Jul 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    163K
    How far from its usual level
    +5.8
    Same report last year
    1.6M
    History used
    1,659 days
    2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M2022-04-29: 2.8M2022-05-13: 2.6M2022-05-31: 2.6M2022-06-15: 2.6M2022-06-30: 2.9M2022-07-15: 3.1M
    the 15 Jul 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 13 Jul 2022Short interest and volume change

    had 2.9M shares sold short in the 30 Jun 2022 report, 1.7× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    2.9M (the 30 Jun 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    129K
    How far from its usual level
    +5.9
    Same report last year
    1.7M
    History used
    1,644 days
    2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M2022-04-29: 2.8M2022-05-13: 2.6M2022-05-31: 2.6M2022-06-15: 2.6M2022-06-30: 2.9M
    the 30 Jun 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 28 Jun 2022Short interest and volume change

    had 2.6M shares sold short in the 15 Jun 2022 report, 1.5× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    2.6M (the 15 Jun 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    121K
    How far from its usual level
    +4.9
    Same report last year
    1.7M
    History used
    1,629 days
    2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M2022-04-29: 2.8M2022-05-13: 2.6M2022-05-31: 2.6M2022-06-15: 2.6M
    the 15 Jun 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 10 Jun 2022Short interest and volume change

    had 2.6M shares sold short in the 31 May 2022 report, 1.5× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    2.6M (the 31 May 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    99K
    How far from its usual level
    +5.4
    Same report last year
    1.7M
    History used
    1,614 days
    2021-05-14: 1.7M2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M2022-04-29: 2.8M2022-05-13: 2.6M2022-05-31: 2.6M
    the 31 May 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 1 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 1 Jun 2022Filings record

    Director or officer change

  38. 25 May 2022Short interest and volume change

    had 2.6M shares sold short in the 13 May 2022 report, 1.5× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    2.6M (the 13 May 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    81K
    How far from its usual level
    +5.1
    Same report last year
    1.7M
    History used
    1,596 days
    2021-04-30: 1.6M2021-05-14: 1.7M2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M2022-04-29: 2.8M2022-05-13: 2.6M
    the 13 May 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 11 May 2022Short interest and volume change

    had 2.8M shares sold short in the 29 Apr 2022 report, 1.8× the same report last year.

    Same report last year: 1.6M; its normal report is 1.7M.

    See the evidence
    This period
    2.8M (the 29 Apr 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    67K
    How far from its usual level
    +6.6
    Same report last year
    1.6M
    History used
    1,582 days
    2021-04-15: 1.6M2021-04-30: 1.6M2021-05-14: 1.7M2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M2022-04-29: 2.8M
    the 29 Apr 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 27 Apr 2022Short interest and volume change

    had 2.3M shares sold short in the 14 Apr 2022 report, 1.4× the same report last year.

    Same report last year: 1.6M; its normal report is 1.7M.

    See the evidence
    This period
    2.3M (the 14 Apr 2022 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    64K
    How far from its usual level
    +3.8
    Same report last year
    1.6M
    History used
    1,567 days
    2021-03-31: 1.5M2021-04-15: 1.6M2021-04-30: 1.6M2021-05-14: 1.7M2021-05-28: 1.7M2021-06-15: 1.7M2021-06-30: 1.7M2021-07-15: 1.6M2021-07-30: 1.7M2021-08-13: 1.6M2021-08-31: 1.6M2021-09-15: 1.6M2021-09-30: 1.7M2021-10-15: 1.6M2021-10-29: 1.6M2021-11-15: 1.7M2021-11-30: 1.8M2021-12-15: 1.7M2022-01-14: 1.6M2022-01-31: 2.1M2022-02-15: 2.1M2022-02-28: 2.3M2022-03-15: 2.5M2022-03-31: 2.2M2022-04-14: 2.3M
    the 14 Apr 2022 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 73 entries; narrow the window or the kind of data to see older ones.

Not listed: 277 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000730272
Ticker
RGEN
Domain
repligen.com
Employer name
Repligen Corporation (1 unverified)
Hq location
MA|WALTHAM|02453 (1 unverified)
Name
908 Devices GmbH, ARTeSYN Biosolutions Holdings Ireland Ltd, ARTeSYN Biosolutions Ireland Limited, Polymem S.A and 13 more
Uei
H9J9D228RFQ9
Wikidata
Q17078090
Wikipedia
Repligen
  • DOL H-1B labor condition applications and PERM certifications100 data points2 Mar 2020 to 17 Aug 2026
  • SEC Form 13F institutional holdings2 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)157 records24 Feb 2016 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1113 data points31 Mar 2009 to 23 Oct 2026
  • SEC Form 4 insider transactions152 records, 476 data points13 May 2016 to 6 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards75 data points24 Aug 2011 to 28 Oct 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026